{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T16:12:24Z","timestamp":1791821544286,"version":"4.3.4"},"reference-count":26,"publisher":"Wiley","issue":"10","license":[{"start":{"date-parts":[[2010,9,23]],"date-time":"2010-09-23T00:00:00Z","timestamp":1285200000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Aliment Pharmacol Ther"],"published-print":{"date-parts":[[2010,11]]},"abstract":"<jats:sec><jats:label\/><jats:p> <jats:italic>Aliment Pharmacol Ther<\/jats:italic> 2010; <jats:bold>32:<\/jats:bold> 1240\u20131248<\/jats:p><\/jats:sec><jats:sec><jats:title>Summary<\/jats:title><jats:p><jats:bold>Background\u2002<\/jats:bold> Nonsteroidal anti\u2010inflammatory drugs (NSAID)\u2010related GI effects vary based on patient characteristics.<\/jats:p><jats:p><jats:bold>Aims\u2002<\/jats:bold> To assess risk factors for NSAID\u2010associated upper GI clinical events and dyspepsia.<\/jats:p><jats:p><jats:bold>Methods\u2002<\/jats:bold> Patients \u226550\u2003years with osteoarthritis or rheumatoid arthritis were randomized to etoricoxib or diclofenac in a prespecified intent\u2010to\u2010treat analysis of three double\u2010blind randomized trials. Potential risk factors for upper GI clinical events (bleeding, perforation, obstruction, or ulcer), complicated events (perforation, obstruction, bleeding) and discontinuations due to dyspepsia were assessed with Cox proportional hazard models.<\/jats:p><jats:p><jats:bold>Results\u2002<\/jats:bold> Significant predictors of clinical events and complicated events included age \u226565\u2003years [hazards ratios (HRs)\u2003=\u20032.25 (1.84\u20132.76), 4.09 (2.82\u20135.92)], prior event [HRs\u2003=\u20032.57 (1.94\u20133.39), 3.23 (2.09\u20135.00)], low\u2010dose aspirin [HRs\u2003=\u20032.34 (1.87\u20132.92), 3.41 (2.33\u20135.00)] and corticosteroid [HRs\u2003=\u20031.85 (1.41\u20132.43), 2.09 (1.29\u20133.38)]. Predictors of discontinuation due to dyspepsia included prior dyspepsia [HR\u2003=\u20031.78 (1.44\u20132.00)], prior event [HR\u2003=\u20031.78 (1.40\u20132.27)] and age \u226565\u2003years [HR\u2003=\u20031.35 (1.16\u20131.57)].<\/jats:p><jats:p><jats:bold>Conclusions\u2002<\/jats:bold> Assessment for age \u226565\u2003years, prior upper GI clinical events and low\u2010dose aspirin use are key in identifying patients who should either avoid NSAIDs or employ management strategies to reduce NSAID\u2010associated upper GI events. Prior dyspepsia or upper GI clinical events and age \u226565\u2003years also predict an increased risk of developing dyspepsia severe enough to necessitate discontinuation of NSAIDs.<\/jats:p><\/jats:sec>","DOI":"10.1111\/j.1365-2036.2010.04465.x","type":"journal-article","created":{"date-parts":[[2010,9,23]],"date-time":"2010-09-23T11:20:30Z","timestamp":1285240830000},"page":"1240-1248","source":"Crossref","is-referenced-by-count":69,"title":["Risk factors for NSAID\u2010associated upper GI clinical events in a long\u2010term prospective study of 34\u2003701 arthritis patients"],"prefix":"10.1111","volume":"32","author":[{"given":"L.","family":"Laine","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S. P.","family":"Curtis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Cryer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Kaur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C. P.","family":"Cannon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2010,9,23]]},"reference":[{"key":"e_1_2_6_2_2","doi-asserted-by":"publisher","DOI":"10.1097\/00005344-200605001-00011"},{"key":"e_1_2_6_3_2","doi-asserted-by":"publisher","DOI":"10.1002\/1529-0131(200004)43:4<917::AID-ANR25>3.0.CO;2-F"},{"key":"e_1_2_6_4_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF02599040"},{"issue":"2","key":"e_1_2_6_5_2","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/0002-9343(88)90250-1","article-title":"Direct medical costs of disease and gastrointestinal side effects during treatment for arthritis","volume":"84","author":"Bloom BS","year":"1986","journal-title":"Am J Med"},{"key":"e_1_2_6_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2006.04.010"},{"key":"e_1_2_6_7_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.2008.03905.x"},{"key":"e_1_2_6_8_2","doi-asserted-by":"publisher","DOI":"10.1038\/ajg.2009.115"},{"key":"e_1_2_6_9_2","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2005.08.003"},{"key":"e_1_2_6_10_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.2009.04090.x"},{"key":"e_1_2_6_11_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-123-4-199508150-00001"},{"key":"e_1_2_6_12_2","doi-asserted-by":"publisher","DOI":"10.1053\/gast.2002.36013"},{"key":"e_1_2_6_13_2","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2007.04.045"},{"key":"e_1_2_6_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ahj.2006.05.024"},{"key":"e_1_2_6_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(06)69666-9"},{"key":"e_1_2_6_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(07)60234-7"},{"key":"e_1_2_6_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2007.03.011"},{"key":"e_1_2_6_18_2","doi-asserted-by":"publisher","DOI":"10.1136\/gut.28.5.527"},{"key":"e_1_2_6_19_2","doi-asserted-by":"publisher","DOI":"10.1136\/gut.32.7.730"},{"key":"e_1_2_6_20_2","doi-asserted-by":"publisher","DOI":"10.3109\/00365529609031975"},{"key":"e_1_2_6_21_2","doi-asserted-by":"crossref","first-page":"1530","DOI":"10.1001\/archinte.1996.00440130066007","article-title":"Gastrointestinal tract complications of nonsteroidal anti\u2010inflammatory drug treatment in rheumatoid arthritis. A prospective observational cohort study","volume":"156","author":"Singh G","year":"1996","journal-title":"Arch Intern Med"},{"key":"e_1_2_6_22_2","doi-asserted-by":"publisher","DOI":"10.1136\/gut.38.3.316"},{"key":"e_1_2_6_23_2","unstructured":"FDA Arthritis Advisory Committee Meeting. February 7 2001. Available at:http:\/\/www.fda.gov\/ohrms\/dockets\/ac\/01\/briefing\/3677b1.htm."},{"key":"e_1_2_6_24_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200011233432103"},{"key":"e_1_2_6_25_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(04)16893-1"},{"key":"e_1_2_6_26_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.2007.03358.x"},{"key":"e_1_2_6_27_2","doi-asserted-by":"publisher","DOI":"10.1097\/00004836-198904000-00009"}],"container-title":["Alimentary Pharmacology &amp; Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-2036.2010.04465.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1365-2036.2010.04465.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,31]],"date-time":"2023-10-31T20:21:07Z","timestamp":1698783667000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1365-2036.2010.04465.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,9,23]]},"references-count":26,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2010,11]]}},"alternative-id":["10.1111\/j.1365-2036.2010.04465.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1365-2036.2010.04465.x","archive":["Portico"],"relation":{},"ISSN":["0269-2813","1365-2036"],"issn-type":[{"value":"0269-2813","type":"print"},{"value":"1365-2036","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,9,23]]}}}